Trintellix Tablet, Film Coated
Product Images NDC 70518-4483

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Trintellix (NDC 70518-4483). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of a medication labeled as Trintellix Tablet containing Vortioxetine, with a strength of 5 mg. Each box contains 30 tablets. It is repackaged by RemedyRepack Inc. in Indiana, PA, with an NDC number of 70518-4483-00. The manufacturer is Takeda Pharma. Am., Inc., located in Deerfield, IL. The usual dosage instructions can be found in the insert. The medication should be stored at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Remember to keep this medication out of reach of children.*

FDA Label Image

Mm2 (Trintellix 5mg 70518 4483 01)

This text provides information about a Trintellix Tablet containing Vortioxetine of 5 mg. It includes details such as quantity, NDC number, expiration date, usual dosage instructions, repackaging information, manufacturer information, storage instructions, and a reminder to keep the medication out of the reach of children. The tablet is repackaged by RemedyRepack Inc. and manufactured by Takeda Pharma. Am., Inc.*

FDA Label Image

Chemical Structure (Trintellix 01)

FDA Label Image

Figure 1 (Trintellix 02)

FDA Label Image

Figure 2 (Trintellix 03)

This text provides a list of interacting drugs grouped by their effects on various liver enzymes such as CYP2D6 inhibitor (Bupropion), CYP Inducer (Rifampin), CYP3A/Pgp inhibitor (Ketoconazole), CYP2C02, CYP2C1973A, CYP2C19 inhibitors, and other drugs like Ethanol and Aspirin. It also discusses pharmacokinetic parameters like Cmax and auc, and presents fold change with 90% confidence intervals in relation to vortioxetine alone.*

FDA Label Image

Figure 3 (Trintellix 04)

This text provides a list of interacting drugs categorized by CYP substrate, along with additional information on PK parameters like AUC and Cmax. It also mentions fold change and confidence intervals for the interactions. The information seems to be related to drug metabolism and potential drug-drug interactions.*

FDA Label Image

Figure 4 (Trintellix 05)

This text seems to list different medications, including Placebo and TRINTELLIX at 10mg and 20mg doses, likely used in a study or trial. It also indicates a change from baseline over multiple study visits (weeks).*

FDA Label Image

Figure 5 (Trintellix 06)

This text appears to be a list showing different studies conducted on TRINTELLIX at various doses (5mg, 10mg, 15mg, 20mg) in different settings (US and Non-US), including a study specifically focused on the elderly. The studies compare TRINTELLIX at different doses against a placebo to evaluate its effectiveness.*

FDA Label Image

Figure 6 (Trintellix 07)

This appears to be a comparison of the drug Trintellix (50-10mg) with a placebo at different time points in terms of the proportion of patients with recurrence. The data shows the number of patients maintained on each treatment and the time to recurrence in weeks. The chart indicates the efficacy of Trintellix in comparison to the placebo in preventing recurrence over time.*

FDA Label Image

Figure 7 (Trintellix 08)

Not available.*

FDA Label Image

Figure 8 (Trintellix 09)

This text seems to outline changes in improvement from baseline for two medications, Trintellix and Escitalopram, at doses of 10 or 20mg. The data provided may be related to a comparison of the effectiveness of these medications in achieving improvement.*

FDA Label Image

Figure 9 (Trintellix 10)

This text seems to be a comparison chart or table showing the results of a study visit over a period of time, likely focusing on the effects of different medications on a specific condition. The medications mentioned include Placebo, Trintelix at doses of 10mg and 20mg, and Paroxetine at 20mg. The numbers 1, 2, 3, and 3 may denote different time points or categories related to the study.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.